Corporate ActionJul 23, 2026, 08:35 AM
20/20 BioLabs enters standstill to limit stock dilution
AI Summary
20/20 BioLabs, Inc. announced a standstill agreement with Streeterville Capital, LLC, effective July 16, 2026. This agreement temporarily restricts Streeterville from converting its Series E Convertible Preferred Stock into common stock for 120 days, unless the common stock trades at least 10% above the Nasdaq Minimum Price. The purpose of this agreement is to mitigate potential near-term dilution while preserving existing rights and obligations.
Key Highlights
- 20/20 BioLabs entered a standstill agreement with Streeterville Capital, LLC.
- The agreement relates to the Company's outstanding Series E Convertible Preferred Stock.
- Streeterville agreed not to convert Series E Preferred Stock for 120 days, effective July 16, 2026.
- Conversions are restricted unless common stock trades at least 10% above the Nasdaq Minimum Price.
- The agreement temporarily limits potential dilution from preferred stock conversions.
Price Impact
More from AIDX